Zevra Therapeutics (ZVRA) shares ended the last trading session 6.6% higher at $6.14. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock’s 1% loss over the past four weeks.
The sudden surge in the stock price can be attributed to the positive investor mindset regarding the company’s pipeline candidates. Zevra’s new drug application for arimoclomol, to treat Niemann-Pick disease type C, is currently under review with the FDA. A decision from the regulatory body is expected in June 2024. The company’s commercial portfolio currently comprises its only marketed product in the United States, Azstarys, for the treatment of attention deficit hyperactivity disorder in patients aged six years and older.
This specialty pharmaceutical company is expected to post quarterly loss of $0.19 per share in its upcoming report, which represents a year-over-year change of +26.9%. Revenues are expected to be $13.52 million, up 482.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Zevra Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock’s price usually doesn’t keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ZVRA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here >>>>
Zevra Therapeutics is a member of the Zacks Medical – Drugs industry. One other stock in the same industry, OptiNose (OPTN), finished the last trading session 6.3% higher at $1.35. OPTN has returned 0% over the past month.
For OptiNose
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.
It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Zevra Therapeutics, Inc. (ZVRA) : Free Stock Analysis Report
OptiNose, Inc. (OPTN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Image and article originally from www.nasdaq.com. Read the original article here.